Randomized double blind, placebo controlled, parallel group trial to evaluate the safety and efficacy of CT1812 in early alzheimer's disease over 18 months
Active Project Grant Awarded Last action
- Award ID
- R01AG065248
- Recipient
-
Cognition Therapeutics, Inc. UEI NUNHAKQ7MS86
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $110,264,121
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 91% complete
- Originally
- Funding
-
- $95,497,453.00 Federal
- $14,766,668.00 Non-federal
- Place of performance
- Carson, PA 15203, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $16,494,670 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $11,955,061 | $0 | |
| Amendment | $13,127,747 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $14,619,478 | $0 | |
| Amendment | $14,619,478 | $14,619,478 | |
| Amendment | $147,190 | $0 | |
| Amendment | $147,190 | $147,190 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $2,058,609 | $0 | |
| Original award | $22,328,030 | $0 |
Show all 22
Quick answers
Who received award R01AG065248?
R01AG065248 was awarded to Cognition Therapeutics, Inc. by National Institute on Aging (National Institutes of Health) on June 1, 2020.
How much is award R01AG065248 worth?
$110,264,121 has been obligated on R01AG065248: $95,497,453 in federal funding and $14,766,668 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award